These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23385888)

  • 1. Long-term efficacy and safety of sitagliptin in the treatment of Japanese Type 2 diabetes (ASSET-K1) to a target of HbA1c <7%.
    Maeda H; Kubota A; Kanamori A; Tanaka Y; Terauchi Y; Matsuba I;
    J Endocrinol Invest; 2013 Sep; 36(8):568-73. PubMed ID: 23385888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.
    Harashima SI; Tanaka D; Yamane S; Ogura M; Fujita Y; Murata Y; Seike M; Koizumi T; Aono M; Wang Y; Inagaki N
    Horm Metab Res; 2013 Mar; 45(3):231-8. PubMed ID: 22972180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy.
    Shimoda S; Iwashita S; Ichimori S; Matsuo Y; Goto R; Maeda T; Matsuo T; Sekigami T; Kawashima J; Kondo T; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2013; 60(10):1207-14. PubMed ID: 23912974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of concomitant drugs on sitagliptin-mediated improvement in glycemic control in Japanese patients with type 2 diabetes.
    Hirata T; Inukai K; Morimoto J; Katayama S; Ishida H
    Prim Care Diabetes; 2014 Oct; 8(3):265-70. PubMed ID: 24530100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
    Yang W; Guan Y; Shentu Y; Li Z; Johnson-Levonas AO; Engel SS; Kaufman KD; Goldstein BJ; Alba M
    J Diabetes; 2012 Sep; 4(3):227-37. PubMed ID: 22672586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.
    Maeda H; Kubota A; Tanaka Y; Terauchi Y; Matsuba I;
    Diabetes Res Clin Pract; 2012 Jan; 95(1):e20-2. PubMed ID: 22055835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.
    Umayahara R; Yonemoto T; Kyou C; Morishita K; Ogawa T; Taguchi Y; Inoue T
    Endocr J; 2014; 61(12):1163-70. PubMed ID: 25168659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting steady-state HbA1c responses to sitagliptin in patients with type 2 diabetes mellitus.
    Kanazu S; Horie Y; Narukawa M; Nonaka K; Taniguchi T; Arjona Ferreira JC; Takeuchi M
    Diabetes Obes Metab; 2009 Aug; 11(8):813-8. PubMed ID: 19476471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Dobs AS; Goldstein BJ; Aschner P; Horton ES; Umpierrez GE; Duran L; Hill JS; Chen Y; Golm GT; Langdon RB; Williams-Herman DE; Kaufman KD; Amatruda JM; Ferreira JC
    J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barzilai N; Guo H; Mahoney EM; Caporossi S; Golm GT; Langdon RB; Williams-Herman D; Kaufman KD; Amatruda JM; Goldstein BJ; Steinberg H
    Curr Med Res Opin; 2011 May; 27(5):1049-58. PubMed ID: 21428727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes.
    Vilsbøll T; Rosenstock J; Yki-Järvinen H; Cefalu WT; Chen Y; Luo E; Musser B; Andryuk PJ; Ling Y; Kaufman KD; Amatruda JM; Engel SS; Katz L
    Diabetes Obes Metab; 2010 Feb; 12(2):167-77. PubMed ID: 20092585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.
    Derosa G; Ragonesi PD; Fogari E; Cicero AF; Bianchi L; Bonaventura A; Romano D; Maffioli P
    Fundam Clin Pharmacol; 2014 Apr; 28(2):221-9. PubMed ID: 23039403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
    Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
    Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.